Takeda Pharma Discloses 1.84M Share Stake in Equillium

TL;DR

**Takeda owns 1.84M Equillium shares, signaling big pharma's continued interest.**

AI Summary

Takeda Pharmaceutical Company Limited, a Japanese pharmaceutical giant, reported beneficial ownership of 1,842,977 shares of Equillium, Inc. common stock as of December 31, 2023. This represents a significant stake, indicating Takeda's continued interest in Equillium. For investors, this matters because a major pharmaceutical company holding a substantial position can signal confidence in Equillium's future prospects or potential strategic collaboration.

Why It Matters

This filing shows a major pharmaceutical company, Takeda, maintains a significant investment in Equillium, which could be a positive signal for Equillium's stability and future potential partnerships.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of ownership and does not indicate any immediate negative risks for Equillium.

Analyst Insight

An investor should note Takeda's continued ownership as a potential indicator of long-term interest in Equillium, but this filing alone doesn't suggest immediate action. It's a data point for broader due diligence.

Key Numbers

• 1,842,977 — Shares Beneficially Owned (Represents Takeda's shared voting and dispositive power over Equillium stock.)
• 0 — Sole Voting Power (Indicates Takeda does not have exclusive control over these shares' voting rights.)
• 0 — Sole Dispositive Power (Indicates Takeda does not have exclusive control over selling these shares.)
• December 31, 2023 — Event Date (The specific date on which the ownership stake was determined for this filing.)

Key Players & Entities

• Takeda Pharmaceutical Company Limited (company) — reporting person and beneficial owner
• Equillium, Inc. (company) — issuer of the securities
• 1,842,977 (dollar_amount) — number of shares beneficially owned
• December 31, 2023 (date) — date of event requiring the filing
• Japan (country) — place of organization for Takeda

Forward-Looking Statements

• Takeda will maintain its significant stake in Equillium for the foreseeable future. (Takeda Pharmaceutical Company Limited) — medium confidence, target: 2025-12-31
• Equillium may explore further collaborations or partnerships with Takeda given their existing investment. (Equillium, Inc.) — low confidence, target: 2024-12-31

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• sc13g_011924.htm (SC 13G) — 64KB
• exhibit991_011924.htm (EX-99.1) — 2KB
• exhibit992_011924.htm (EX-99.2) — 7KB
• 0001395064-24-000004.txt ( ) — 74KB

(a) Name of issuer

Item 1(a) Name of issuer Equillium, Inc. (the "Issuer").

(b) Address of issuer's principal executive offices

Item 1(b) Address of issuer's principal executive offices 2223 Avenida De La Playa, Suite 105 La Jolla, CA 92037

(a) Name of person filing

Item 2(a) Name of person filing Takeda Pharmaceutical Company Limited Takeda Ventures, Inc.

(b) Address of principal business office or, if none, residence

Item 2(b) Address of principal business office or, if none, residence Takeda Pharmaceutical Company Limited – 1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo M0 103-8668, Japan Takeda Ventures, Inc. – 9625 Towne Centre Drive, San Diego, CA 92121

(c) Citizenship

Item 2(c) Citizenship Takeda Pharmaceutical Company Limited is a corporation formed under the laws of Japan. Takeda Ventures, Inc. is a corporation formed under the laws of the State of Delaware.

(d) Title of class of securities

Item 2(d) Title of class of securities Common Stock, par value $0.0001 per share

(e) CUSIP No

Item 2(e) CUSIP No. 29446K106

If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a

Item 3. If this statement is filed pursuant to 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a Not applicable.

Ownership

Item 4. Ownership Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned See the responses in Row 9 on the attached cover pages. (b) Percent of class See the responses in Row 11 on the attached cover pages. (c) Number of shares as to which the person has (i) Sole power to vote or to direct the vote See the responses in Row 5 on the attached cover pages. (ii) Shared power to vote or to direct the vote See the responses in Row 6 on the attached cover pages. (iii) Sole power to dispose or to direct the disposition of See the responses in Row 7 on the attached cover pages. (iv) Shared power to dispose or to direct the disposition of See the responses in Row 8 on the attached cover pages. Page 4 of 6 pages The percentages used herein and in this Item 4 are calculated based on 35,119,248 shares of Common Stock issued and outstanding as of November 6, 2023, as reported in the Issuer's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on November 8, 2023.

Ownership of 5 Percent or Less of a Class

Item 5. Ownership of 5 Percent or Less of a Class. Not applicable.

Ownership of More than 5 Percent on Behalf of Another Person

Item 6. Ownership of More than 5 Percent on Behalf of Another Person. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. See Exhibit 99.1.

Identification and Classification of Members of the Group

Item 8. Identification and Classification of Members of the Group. Not applicable.

Notice of Dissolution of Group

Item 9. Notice of Dissolution of Group. Not applicable.

Certifications

Item 10. Certifications By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11. Page 5 of 6 pages

Signatures

Signatures After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Dated January 18, 2024 TAKEDA PHARMACEUTICAL COMPANY LIMITED By s Yoshihiro Nakagawa Name Yoshihiro Nakagawa Title Global General Counsel TAKEDA VENTURES, INC. By s Paul Sundberg Name Paul Sundberg Title Assistant Secretary Page 6 of 6 pages INDEX TO EXHIBITS Exhibit 99.1 Identification of the subsidiary which acquired the security being reported on by the parent holding company Exhibit 99.2 Joint Filing Agreement

View Full Filing

View this SC 13G filing on SEC EDGAR